Article courtesy of Cancer Research UK.

A targeted drug has been accepted for routine use on the NHS in England for some adults with untreated, advanced lung cancer. But another precision drug, for the same group of patients, has been rejected due to questions over its cost-effectiveness. 

Read the full article here: http://bit.ly/2LEGnx4